Businesses have money on the line. If course they
Post# of 22453
The problem with vaccine passports are that 1. not everyone is vaccinated or even wants to be vaccinated, thus limiting the pool of available customers and 2. there is no guarantee vaccination insures no reinfection and transmission.
For all situations, 3. antigen tests are best for proving negative Covid status in a one to three day window before flight or event.
The U.S. Biden administration stated they won't pursue a government vaccine database but leave it to private enterprise. Other countries, especially in Europe with more socialized medicine are connecting vaccine records to their national health system records.
While QMCH was developed to keep the test/vaccine records privacy up to the testee, the truth is whoever pays for the tests/vaccine owns the results. If France pays, France owns. The only option is to not get tested/vaccinated and to stay out of the system, at the cost of your freedom to do things that government considers a public health risk, work, events, travel.
Short term, it is in the public interest to have everyone tested and vaccinated to reduce and control the spread of Covid.
Long term, a database of vaccination can be used to help determine the effectiveness and future timing of additional testing for antibodies and booster shots. That's the example of it's use for the public good.
Some others might see it as forcing vaccination on the unwilling. They object to being kept from work, school, travel, and events for not having vaccination.
For the reasons in paragraphs 2 and 3, numbered 1, 2 and 3, I believe Health/Travel Passes should focus on antigen test results immediately before whatever activity the testee is attending, within no more than a 48 hour window, as the only way to ensure the testee is not infectious currently. Inexpensive Antigen tests with results within 20 minutes can accomplish this with only a small amount of inconvenience. Any positive Covid result is retested to confirm positive or prove a false positive.
In the case of the CITI Innova/QMCH test, results go to only the parties conducting the test and the Testee unless the testee shares the results with other organizations that require a recent negative test.
It's possible countries with their own NHS could still hookup QMCH aspects to run in parallel with their own systems, to take advantage of QMCH proprietary and unique features. In that case we might never hear who is using QMCH, but only see the revenue generated. It's not hard to develop different user interfaces or translations for them.